Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 4/2019

01-08-2019 | Metastasis | Research Paper

Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

Authors: V. Dell’Acqua, A. Surgo, F. Kraja, J. Kobiela, Maria Alessia Zerella, P. Spychalski, S. Gandini, C. M. Francia, D. Ciardo, C. Fodor, A. M. Ferrari, G. Piperno, F. Cattani, S. Vigorito, F. Pansini, W. Petz, R. Orecchia, M. C. Leonardi, B. A. Jereczek-Fossa

Published in: Clinical & Experimental Metastasis | Issue 4/2019

Login to get access

Abstract

To evaluate the local control (LC), progression free survival (PFS), out-field PFS, overall survival (OS), toxicity and failure predictors of SRT in a series of various sites oligometastatic CRC patients. Patients with oligometastatic CRC disease were analyzed retrospectively. The SRT prescribed dose was dependent on the lesion volume and its location. 102 consecutive oligometastatic CRC patients (150 lesions) were included. They underwent SRT between 2012 and 2015. Median prescription dose was 45 Gy (median dose/fraction was 15 Gy/3 fractions biological equivalent dose (BED10) 112.5 Gy). Median follow-up was 11.4 months. No patients experienced G3 and G4 toxicity. No progression was found in 82% (radiological response at 3 months) and 85% (best radiological response) out of 150 evaluable lesions. At 1 and 2 years: LC was 70% and 55%; OS was 90% and 90%; PFS was 37% and 27%; out-field PFS was 37% and 23% respectively. Progressive disease was correlated with BED10 (better LC when BED10 was ≥ 75 Gy (p < 0.0001)). In multivariate analysis, LC was higher in lesions with a Plpnning target volume (PTV) volume < 42 cm3 and BED10 ≥ 75 Gy. Patients with Karnofsky performance status < 90 showed higher out-field progression. SRT is an effective treatment for patients with oligometastases from CRC. Its low treatment-associated morbidity and acceptable LC make of SRT an option not only in selected cases. Further studies should be focused to clarify which patient subgroup will benefit most from this treatment modality and to define the optimal dose to improve LC while maintaining low toxicity profile.
Literature
1.
Sahgal A, Roberge D, Schellenberg D et al (2012) The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol (R Coll Radiol) 24:629–639CrossRef
2.
Palma DA, Louie AV, Rodrigues GB (2015) New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res 21:5198–5204CrossRefPubMed
3.
Rusthoven K, Kavanagh B, Burri S et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579–1584CrossRefPubMed
4.
Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed
5.
Siva S, Pham D, Kron T et al (2017) Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 120:623–630CrossRefPubMed
6.
Wang XS, Rhines LD, Shiu AS et al (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13:395–402CrossRefPubMedPubMedCentral
7.
Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed
8.
Franceschini D, Cozzi L, De Rose F et al (2017) Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. J Cancer Res Clin Oncol 143:1293–1299CrossRefPubMed
9.
Wiechselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382CrossRef
10.
11.
12.
Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900–909CrossRefPubMed
13.
Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715–22. Discussion 722–724
14.
Giantonio BJ, Levy DE, O’dwyer PJ, Eastern Cooperative Oncology Group et al (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17:1399–1403
15.
Kavanagh BD, McGarry RC, Timmerman RD (2006) Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16:77–84CrossRefPubMed
16.
17.
Kanemitsu Y, Takakura Y, Miyata Y et al (2010) Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer. Colorectal Dis 12:e68–e75
18.
Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on stereotactic radiotherapy. Strahlenther Onkol 190:872–881CrossRefPubMed
19.
Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342CrossRefPubMed
20.
21.
Ruers T, Van Coevorden F, Punt CJ, European Organisation for Research and Trea tment of Cancer (EORTC), Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG) et al (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. https://​doi.​org/​10.​1093/​jnci/​djx015 CrossRefPubMedPubMedCentral
22.
Ahmed K, Caudell JJ, El-Haddad G et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95(5):1399–1404CrossRefPubMedPubMedCentral
23.
Klement RJ, Guckenberger M, Alheid H et al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease-influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123(2):227–233CrossRefPubMed
24.
Kobiela J, Spychalski P, Marvaso G et al (2018) Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol 129:91–101CrossRefPubMed
25.
Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830CrossRefPubMed
26.
Ricotti R, Seregni M, Ciardo D et al (2018) Evaluation of target coverage and margins adequacy during CyberKnife lung optimized treatment. Med Phys 45(4):1360–1368CrossRefPubMed
27.
Bradley JD, Nofal AN, El Naqa IM et al (2006) Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. Radiother Oncol 81(3):264–268CrossRefPubMed
28.
Timmerman RD (2008) An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 18:215–222CrossRefPubMed
29.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247CrossRefPubMed
30.
31.
Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897CrossRefPubMed
32.
Lazzari R, Ronchi S, Gandini S et al (2018) Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys 101(3):650–660CrossRefPubMed
33.
Jereczek-Fossa BA, Fanetti G, Fodor C et al (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRefPubMed
34.
35.
Adam R, Wicherts D, De Haas R et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clinl Oncol 27:1829–1835CrossRef
36.
Lagerwaard FJ, Aaronson NK, Gundy CM et al (2012) Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 7(7):1148–5437CrossRefPubMed
37.
Holmes OE, Gratton J, Szanto J et al (2018) Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT). Radiosurg SBRT 5(3):217–227
38.
Comito T, Cozzi L, Clerici E et al (2014) Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 14:619CrossRefPubMedPubMedCentral
39.
Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069CrossRefPubMed
40.
Joo JH, Park JH, Kim JC et al (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99(4):876–883CrossRefPubMed
41.
Andratschke N, Alheid H, Allgäuer M et al (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18(1):283CrossRefPubMedPubMedCentral
42.
43.
Ahmed KA, Fulp WJ, Berglund AE et al (2015) Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys 92(4):837–842CrossRefPubMedPubMedCentral
44.
Ricco A, Davis J, Rate W et al (2017) Lung metastases treated with stereotacticbody radiotherapy: the RSSearch® patientRegistry’s experience. Radiat Oncol 12(1):35CrossRefPubMedPubMedCentral
45.
Lee M, Kim J, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed
46.
Bae SH, Kim MS, Cho CK et al (2012) High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. J Surg Oncol 106:138–143CrossRefPubMed
47.
Qiu H, Katz AW, Chowdhry AK et al (2018) Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol 41(1):53–58PubMed
Metadata
Title
Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions
Authors
V. Dell’Acqua
A. Surgo
F. Kraja
J. Kobiela
Maria Alessia Zerella
P. Spychalski
S. Gandini
C. M. Francia
D. Ciardo
C. Fodor
A. M. Ferrari
G. Piperno
F. Cattani
S. Vigorito
F. Pansini
W. Petz
R. Orecchia
M. C. Leonardi
B. A. Jereczek-Fossa
Publication date
01-08-2019
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 4/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-019-09976-z

Other articles of this Issue 4/2019

Clinical & Experimental Metastasis 4/2019 Go to the issue

Commentary

The importance of developing therapies targeting the biological spectrum of metastatic disease

Research Paper

CTHRC1 promotes M2-like macrophage recruitment and myometrial invasion in endometrial carcinoma by integrin-Akt signaling pathway

Research Paper

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: a systematic review

Editorial

Diagnostics of metastasis: an increasing challenge with high clinical importance

Research Paper

Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells

Research Paper

Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits